INDV
Indivior Pharmaceuticals Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$34.94
+0.32%Year over year
Reported trailing growth
- Revenue
- +13.5%
- EBITDA
- +51.0%
- EBIT
- +117.6%
- EPS
- +183.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +0.9%
- EBITDA
- +107.5%
- EPS
- +59.1%
Three-year CAGR
- Revenue
- +11.2%
- EBITDA
- +261.9%
- EBIT
- +728.1%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026